Insurance red tape is blocking blood cancer patients from life-saving oral drugs

A large nationwide study published in the Journal of Clinical Oncology reveals a troubling pattern: most patients with blood cancers face significant barriers to accessing specialty oral anticancer medications — and insurance policies are a primary driver. Researchers analyzed prescription and claims data from over 12,000 patients with leukemia, lymphoma, or myeloma in 2022, finding that initial approval-and-fill rates were strikingly low: just 9.6% for Medicare patients and 4% for commercially insured patients.

While approval rates improved over 90 days (85% for Medicare, 62.8% for commercial), many approved prescriptions still went unfilled. Prior authorization was the top rejection reason, though the majority of those denials were eventually overturned — raising questions about whether the process serves any meaningful clinical purpose.

By the Numbers:

• Only 54.5% of Medicare and 45.5% of commercially insured patients ultimately filled their prescriptions within 90 days
• Fill rates dropped sharply once out-of-pocket costs exceeded $175
• At costs above $2,000, fill rates fell to just 31.2% (Medicare) and 21.6% (commercial)
• 75–86% of prior authorization rejections for Medicare patients were eventually overturned

Why it matters: These findings highlight how insurance utilization management practices and high cost-sharing can delay or deny access to potentially life-saving cancer therapies. Professional societies like ASCO and ASH are calling for reform — and this data provides compelling evidence to support that push.